Bioactive Adrenomedullin, measured with sphingotec's bio-ADM ® assay plays a key role in septic shock as top-line results of AdrenOSS-2 Phase II Study indicate

(sphingotec GmbH) AdrenOSS-2 Phase II trial shows that modulating the Adrenomedullin plasma level with the therapeutic antibody Adrecizumab demonstrates an improvement of survival in patients with septic shock.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news